Nexstim Plc to Present Depression Led Strategy at Investor Conference Sijoittaja 2018 in Helsinki - Seite 2

Martin Jamieson, Chairman and CEO, Nexstim Plc commented: "Nexstim's strategy is now focused on building shareholder value by capitalising on the significant potential of our SmartFocus^TM TMS for the treatment of MDD.  Our technology promises improved outcomes for patients with depression at a time when neuro-stimulation is rapidly gaining traction as a mainstream treatment modality. The unique navigational capability of our NBT system, personalised to each patient for targeted stimulation of the relevant brain area, clearly differentiates it from the non-navigational TMS devices currently on the market for this indication. We are investing in our US commercial organisation to ensure that we can maximise the potential of our unique system in the very large US MDD market."

Martin Jamieson added: "As of 30 June 2018, Nexstim had a cash position of EUR 10.3 million and the current cash balance and cash generated from sales will finance the Company until the end of Q2 2019.
The Company is actively evaluating the possibility for a new fund raising during H2 2018 to support our commercialisation of the NBT system. I look forward to keeping you updated on the progress we are making in executing our new MDD focused strategy."

***

Conference Call/ Webcast Details

The Company will host a conference call and an online presentation on Tuesday 25^th September 2018 at 4:00 p.m. EEST  (3:00 p.m. CEST / 9:00 a.m. EDT).

The dial-in numbers for the conference call are:

FI: [phone]
SE: [phone]
UK: [phone]
US: [phone]

Confirmation Code:  8851156

Webcast
The presentation will also be webcast and can be accessed from the following web address:
https://nexstim.com/news-and-events/events/event/news/nexstim-conferen ...

Hosts: Martin Jamieson, CEO, and Mikko Karvinen, CFO

***

Further information is available on the website www.nexstim.com or by contacting:

Nexstim                                               [phone]
Martin Jamieson, Chairman and CEO  [e-mail]

Citigate Dewe Rogerson             [phone]
David Dible/ Shabnam Bashir/ Sylvie Berrebi [e-mail]

About Nexstim Plc

Nexstim is a medical technology company focused on the development  and commercialization of its world-leading SmartFocus^TM TMS technology, a non-invasive brain stimulation system for the treatment of Major Depressive Disorder (MDD). The Company's proprietary Navigated Brain Therapy (NBT) system, a highly sophisticated 3D navigation, is the only personalised, navigated transcranial magnetic stimulation (TMS) approach providing accurate targeting of the TMS to the specific area of the brain associated with MDD.